12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

STX209: Phase IIb data

The double-blind, U.S. Phase IIb Study 209AS208 in 150 patients ages 5 to 21 years with ASD showed that oral STX209 for 12 weeks missed the primary endpoint of reducing patient-rated ABC-LSW subscale scores from baseline to week 8 vs. placebo (5.3 vs. 6.1 points, p=0.477). STX209 did meet the secondary endpoint of reducing CGI-S scores vs. placebo (0.7 vs. 0.3 points, p=0.009), but missed the secondary endpoints of improving CGI-I (3.1 vs....

Read the full 341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >